Centrexion Therapeutics Expands Pain Pipeline with Acquisition of Three New Analgesic Candidates from Boehringer Ingelheim

March 30, 2016 07:00 AM Eastern Daylight Time
BALTIMORE­­(BUSINESS WIRE)­­Centrexion Therapeutics, a company focused on advancing chronic pain treatment with new non­opioid and non­surgical therapies, today announced the expansion of its proprietary pipeline with the acquisition of three new analgesic candidates from Boehringer Ingelheim. The company’s proprietary pipeline consists of the first and only injectable analgesic capsaicin, known as trans­capsaicin, which is currently being evaluated in clinical trials for the treatment of pain associated with chronic conditions.

This entry was posted in Recent Development News: Q1 - 2016, Recent Developments. Bookmark the permalink.
Read Full Article »